Masayoshi Harigai, MD, PhD is Professor and Head of Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University, Tokyo, Japan. He served as Professor of Department of Pharmacovigilance at Tokyo Medical and Dental University between 2007 and 2015 and has been installed in the present position in 2019. Professor Harigai is the principal investigator of Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis, clinical trial of tocilizumab for ANCA-associated vasculitis, and 2020 Japanese Clinical Practice Guidelines for the Management of Rheumatoid Arthritis. He has been serving as a board member of Japan College of Rheumatology since 2018.
